30 results
8-K
EX-99.1
FUST
Fuse Group Holding Inc.
11 Feb 21
Fuse Group Holding Inc. Entered into Letter of Intent to Acquire
4:15pm
at $1.00 per share for the purpose of this transaction.
E-Mo is involved in biology research and development including vaccines, immunological treatment … .
Mr. Umesh Patel, Chief Executive Office of the Company said, “We are excited about the opportunity to enter into biotech research and development
8-K/A
FUST
Fuse Group Holding Inc.
1 Oct 21
Entry into a Material Definitive Agreement
4:31pm
, development-stage company involving in vaccine, immunological treatment and diagnostic product research and development and currently has … research and development and currently has no commercial sales of vaccines, treatments, or diagnostic products. This Amendment reports events
UPLOAD
FUST
Fuse Group Holding Inc.
12 May 21
Letter from SEC
12:00am
research and development including vaccines, immunological
treatment,
diagnostic product development and similar treatments against the
Severe … advances related to its COVID-19 vaccine, including the dates
of research and
development and of any meaningful progress, to include testing
UPLOAD
FUST
Fuse Group Holding Inc.
24 Sep 21
Letter from SEC
12:00am
is involved in biology research and development including
vaccines,
immunological treatment, diagnostic product development and similar
treatments … represented, most recently in your
June 30, 2021 interim
report, that E-Mo Biotech engages in biology research and
development business
CORRESP
FUST
Fuse Group Holding Inc.
12 Oct 21
Correspondence with SEC
12:00am
in a reverse merger. You initially reported that “E-Mo is involved in biology research and development including vaccines, immunological treatment … ,” and have subsequently represented, most recently in your June 30, 2021 interim report, that “E-Mo Biotech engages in biology research and development
CORRESP
47v2e4tmh xox1y26t
26 May 21
Correspondence with SEC
12:00am
UPLOAD
yvgy3 xt16ixrjij
10 Mar 21
Letter from SEC
12:00am
8-K
c5l9kg
17 Mar 21
Entry into a Material Definitive Agreement
4:00pm
8-K
EX-10.1
8pzmlcp 2uh1816
1 Oct 21
Entry into a Material Definitive Agreement
4:36pm
CORRESP
2enm0 f72
19 Mar 21
Correspondence with SEC
12:00am
10-K
109u5j181vdc33ny
17 Nov 16
Annual report
12:00am